Aravive Inc

Aravive — Versartis — Investor Presentation (November 2016)

41 slides from Aravive's investor presentation, Nov 29, 2016

  1. Slide 1: Versartis Corporate Presentation November 2016

    Versartis Corporate Presentation November 2016 Exhibit 99.1

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and are subject to risks and u

  3. Slide 3: Endocrine-Focused Biopharmaceutical Company Developing Somavaratan

    Endocrine-Focused Biopharmaceutical Company Developing Somavaratan, a Novel, Long-Acting form of Recombinant Human Growth Hormone to Treat the Orphan Disease of Growth Hormone Deficiency

  4. Slide 4: Company Highlights

    Company Highlights Somavaratan Significantly MORE CONVENIENT PRODUCT Versus Current Daily Therapies Intended to Address adherence and TREATMENT OUTCOME Issues In Japan, May Also Address Need for Improved Efficacy Twice-Monthly Dosing Without Significant Trade-Offs to Current Therapy $3B ESTABLISHED

  5. Slide 5: The Versartis Team

    The Versartis Team: Significant Expertise in GHD Manufacturing, Development & Commercialization Jay Shepard President & CEO >33 Years Pharmaceutical, Biotech, Drug Delivery Expertise Commercialization of Specialty Products, M&A Expertise Joshua Brumm CFO Led Successful IPO and Follow on Offering Lea

  6. Slide 6: Late-Stage Clinical Trials Ongoing

    First Indication Potential Future Indications 3 Late-Stage Clinical Trials Ongoing Pre- Clinical Phase 1 Phase 2 Phase 3 BLA Pediatric GHD US, Europe and Canada Phase 3 Japan Phase 2/3 Adult GHD Phase 2 Small for Gestational Age (SGA) Idiopathic Short Stature (ISS) Turner Syndrome XTEN Product Somav

  7. Slide 7: Growth Hormone Deficiency: A Serious Medical Condition

    Growth Hormone Deficiency: A Serious Medical Condition Source: Utah Growth Study, British Society of Endocrinologists Prevalence 3 per 10,000 1 per 10,000 The Impact Serious Consequences of Lack of Treatment Pathologic Degrees of Short Stature and/or Higher Mortality and Morbidity Cardiovascular Cer

  8. Slide 8: Significant Daily Treatment Burden

    Significant Daily Treatment Burden TODAY’S STANDARD OF CARE Limited Science or Innovation in Treatment for Decades … For 7+ Years “I feel like it ruins every single night.” – Parent “That I sometime simply don’t want to do it… I just run away somewhere.” – Child “Yeah. Definitely… every night it’s t

  9. Slide 9: Poor Compliance and Suboptimal Outcomes

    Poor Compliance and Suboptimal Outcomes POOR COMPLIANCE1 with Daily rhGH Injections Percent Skipping Injections Non-Compliant and Skeptical Occasionally Non-Compliant Highly Compliant Nearly 2/3 of Patients are Non-Compliant HV SDS (Mean+ Standard Error) SUBOPTIMAL OUTCOMES2 from Skipping Injections

  10. Slide 10: Where a Child Starts Affects How Much They Grow

    3 EXAMPLES Height Age in Years WHERE a Child STARTS Affects HOW MUCH They GROW Sources: US NIH Growth Chart for Boys, NIH Height SDS Calculator for Boys Age Baseline Height 96.6 cm Standard Deviations -3.9 106.2 cm -3.2 112.8 cm -2.5 Age in Years 6.29 Years 7.39 Years 7.83 Years MORE Catch-Up Growth

  11. Slide 11: $3B Daily rhGH Global Market Is Undifferentiated and Poised for Growth

    $3B Daily rhGH Global Market Is Undifferentiated and Poised for Growth Source: Market Research 2015 and Company Analysis Novo Nordisk (Norditropin) Pfizer (Genotropin) Eli Lilly (Humatrope) Sandoz (Omnitrope) Merck KGaA (Saizen, Serostim) Roche (Nutropin) Others Fragmented Competition Based on Histo

  12. Slide 12: Somavaratan Our Solution: A Simple, Longer Acting Treatment

    Somavaratan Our Solution: A Simple, Longer Acting Treatment Without Trade-offs 365/year High DOSING FREQUENCY 24/year Low Pens High DEVICE COMPLEXITY Auto-injector Low 30 – 32 NEEDLE GAUGE 29 – 30 Refrigerated (Some: Room Temp) STORAGE REQUIREMENTS Room Temp Daily rhGH

  13. Slide 13: Somavaratan: Novel, Proprietary Molecule

    Somavaratan: Novel, Proprietary Molecule Increased Time on Target XTEN1 Long Tail of Hydrophilic Amino Acids Reduce Kidney Filtration XTEN2 Short Tail of Hydrophilic Amino Acids Reduce Receptor Mediated Clearance rhGH Same Sequence as Approved Products 1. Cleland et al. J Pharm Sci. 2012;101(8):2744

  14. Slide 14: Patients on Somavaratan See Clinically Meaningful Improvements in Efficacy Markers

    Patients on Somavaratan See Clinically Meaningful Improvements in Efficacy Markers Safety IGF-I Catch Up Growth Bone Growth Target Adult Height

  15. Slide 15: Comparable Bone Growth Between Daily rhGH and Somavaratan

    Comparable Bone Growth Between Daily rhGH and Somavaratan Bone growth within all regions of the epiphyseal plate were comparable GHD Control Somavaratan Bone Growth

  16. Slide 16: Results of Somavaratan Twice-Monthly Dosing

    Results of Somavaratan Twice-Monthly Dosing & Increase in the First Two Years of Treatment IGF-I SDS (mean, ±SD) Year 1 2.5 mg/kg Twice-Monthly n=19 Year 2 3.5 mg/kg Twice-Monthly n=57 IGF-I SDS for Subjects Receiving Doses of 2.5 mg/kg Twice-Monthly in Year 1 and 3.5 mg/kg in Year 2 Upper Therapeut

  17. Slide 17: IGF-1 Levels with Somavaratan

    46.6 μg/kg/day 48.9 μg/kg/day 50.4 μg/kg/day 51.4 μg/kg/day 51.0 μg/kg/day 49.6 μg/kg/day Baseline Year 1 Year 2 Year 3 Year 4 Year 5 IGF-1 Levels with Somavaratan Phase 3 Dose within Range of ANSWER Registry Data of Norditropin Daily IGF-I SDS Growth hormone dose (μg/kg/day) and serum IGF-I SDS fro

  18. Slide 18: PGHD Study Results: Safety

    PGHD Study Results: Safety Treatment-Related Adverse Events (AEs) Occurring in >1 Subject Adverse Event, n (%) Treatment Period Months 0-6 (n=64) Months 6-12 (n=60) Months 12-18 (n=57) Months 18-24 (n=53) Months 24-30 (n=48) All AEs 34 (53) 10 (17) 6 (11) 4 (8) 6 (13) Injection site pain 31 (48) 6 (

  19. Slide 19: Current Follow-up Information From VISTA

    Current Follow-up Information From VISTA Previously disclosed rare occurrences of NAbs (antibodies specific to rhGH domain) in vitro cell-based assay Follow-up data indicate no clinical impact associated with positive assay result Bioanalytical findings not predictive of clinical response at 3 years

  20. Slide 20: Results: Catch Up Growth

    Results: Catch Up Growth – Bone Age and Chronologic Age from Baseline through Year 2 Catch-Up Growth Target Adult Height

  21. Slide 21: Height Velocity Update: Mean HV By Original Dose and Regimen

    2 Year Height Velocity Update: Mean HV By Original Dose and Regimen Somavaratan Dosed 3.5 mg/kg Twice-Monthly Resulted in Year 2 HV Comparable to Year 1 Mean HV ±SD, cm/year 5.0 mg/kg Monthly 3.5 mg/kg Twice-Monthly 2.5 mg/kg Twice-Monthly 3.5 mg/kg Twice-Monthly Year 1 Year 1 Year 2 Year 2 Mean HV

  22. Slide 22: Efficacy Comparators Study: Second Year Height Velocity

    Year 2 Efficacy Comparators Study Second Year Height Velocity (cm/year) Somavaratan – 3.5 mg/kg Twice Monthly All subjects with 2-year data (n=57) 7.8 (±2.27) Subjects treated with 5.0 mg/kg Monthly in Year 1 (n=21) 8.3 (±2.80) Subjects treated with 2.5 mg/kg Twice-Monthly in Year 1 (n=17) 8.2 (±1.5

  23. Slide 23: PGHD Data Key Learnings

    PGHD 2 Year Data Key Learnings Phase 3 dose selection supported by VISTA study results for subjects switched to 3.5 mg/kg twice-monthly Mean peak IGF-I SDS at Phase 3 dose was in upper half of normal range Catch-up growth supported by mean increase in bone age and height age exceeding years on study

  24. Slide 24: Pediatric Phase 3 VELOCITY Trial Enrollment Complete

    Pediatric Phase 3 VELOCITY Trial Enrollment Complete Naïve to treatment, Pre-pubertal GHD Somavaratan 3.5 mg/kg Twice-Monthly 34 µg/kg/day 3:1 Randomization Daily rhGH (Similar Inclusion / Exclusion to Phase 2a) Open Label, Randomized Non-Inferiority Design Somavaratan Dose Selection Validated by Lo

  25. Slide 25: A Range of Expectations for First Year Growth

    A Range of Expectations for First Year Growth Twice-Monthly Somavaratan Well Positioned in the Range with Potential For Enhanced Growth on Higher Phase 3 Dose Historical Databases Versartis Market Research 8.5 cm Somavaratan Year 1 HV with Twice-monthly, 2.5 mg/kg 1. Summary Basis of Approval NDA 19

  26. Slide 26: Status of Pediatric GHD Clinical Development Program

    Status of Pediatric GHD Clinical Development Program Phase 1b: PK/PD Model to Select Dose/Regimen Phase 2a: Primary Endpoint 6 Month Mean Height Velocity Phase 1b/2a COMPLETED Long-Term Safety Study Open to All Children Completing Phase 2a or Phase 3 95% of Phase 2a Patients Rolled Over GHD Children

  27. Slide 27: PGHD Development Summary

    PGHD Development Summary Versartis clinical development program has been strategic and intentional: Long term safety data - 4 years at time of BLA submission, 5 years at time of launch Clinical studies in geographies representative of current PGHD market Hands-on somavaratan experience for PGHD trea

  28. Slide 28: Adult GHD Phase 2: Objectives & Design

    Adult GHD Phase 2: Objectives & Design Versartis International Trial in Adults with Long Acting Growth Hormone Objectives Evaluation of the safety of individualized dosing of somavaratan Evaluation of the starting doses for each cohort Evaluation of the dose titration plan for each cohort Phase 2, O

  29. Slide 29: Pharmacodynamic Response

    Pre-dose Day 7 post-dose Day 21 post-dose Day 28 post-dose Pharmacodynamic Response Mean IGF-I (SD) Throughout Dosing Interval & Study Duration (n=36) Robust IGF-I Response Data Suggest Lower Starting Dose and Shorter Dosing Interval -1.0 2.07 -0.52 -0.93 IGF-I SDS

  30. Slide 30: Starting Dose & Titration Plan

    Starting Dose & Titration Plan Somavaratan IGF-I response was robust IGF-I values returned to pre-dose levels by 21 days post dose Titration plan was not ideal to address the high IGF-I at Day 7 No IGF-I associated clinically relevant adverse events 20 mg is the starting dose selected to maintain IG

  31. Slide 31: Phase 2 Trial: Established Foundation for Phase 3

    Phase 2 Trial: Established Foundation for Phase 3 Somavaratan was safe and well tolerated Starting dose, frequency, titration plan & population to be evaluated in ongoing extension study Data available before initiation of Phase 3 Opportunity to confirm elements of Phase 3 design prior to start of t

  32. Slide 32: Single-Use Auto-injector

    Single-Use Auto-injector Designed for Ease of Use, Safety, Comfort Simple injection procedure Suitable for self-injection >8 years Room Temp Storage Disposable 29G thin-wall needle Multiple options with fine dosing adjustments Note: Manufacturing and Supply Agreement for auto-injector with Owen Mumf

  33. Slide 33: Unique Japanese Market Opportunity

    Unique Japanese Market Opportunity JAPAN $0.5B Pediatric $0.6B ~20% of the global rhGH market and ~30% of Pediatric GHD Approved Dose in Japan is the Lowest Dose of Any Developed Country Leads to Suboptimal Growth Outcomes Historical Dose Issue Somavaratan May Demonstrate Better Efficacy Potential f

  34. Slide 34: Versartis and Teijin Establish Strategic Alliance in Japan

    Versartis and Teijin Establish Strategic Alliance in Japan Teijin receives exclusive license to commercialize & further develop somavaratan in Japan Versartis to receive $40 million upfront, and up to $125 million in potential milestones: Development milestone of $35 million Regulatory milestones up

  35. Slide 35: Teijin Transaction is a Strong Strategic Fit

    Teijin Transaction is a Strong Strategic Fit 6th largest Japanese company in Pharmaceutical sales Licensing partnerships with Merck, Ipsen, Boehringer Ingelheim, Takeda & Sanofi Highly Successful commercial track record in very competitive product areas of ENDOCRINE & METABOLIC DISEASES Existing fra

  36. Slide 36: Somavaratan's Data to Date

    Somavaratan’s Data to Date Our Focus Market Expectations Planned Commercial Readiness Somavaratan continues to demonstrate a strong safety and efficacy profile as seen in 24-month data VISTA study patients starting 4th year of treatment on somavaratan Evidence that somavaratan is working in patients

  37. Slide 37: Significant Potential Catalysts to Drive Future Value

    Significant Potential Catalysts to Drive Future Value PEDIATRIC GHD 2017: Initiate Phase 3 Trial 2017: Complete Phase 3 VELOCITY trial September 2016: Phase 3 Initiated Q3 2017: Topline VELOCITY Results Expected 2018: Expected BLA & MAA Ongoing: 4 years data at time of BLA submission, 5 years at tim

  38. Slide 38: Appendix

    v y Appendix

  39. Slide 39: VISTA Study Design

    VISTA Study Design 1. Moore et al. J Clin Endocrinol Metab. 2016;101(3):1091-1097. 5.0 mg/kg Monthly 3.5 mg/kg Twice-Monthly 6–12 Months 12–30 Months (ongoing) 0–6 Months Somavaratan Dose Interval Phase 2a (Repeat Dose) VISTA: Long-Term Safety Study 2.5 mg/kg Twice-Monthly 1.15 mg/kg Weekly 5.0 mg/k

  40. Slide 40: The VISTA Study

    The VISTA Study Previously known as the 13VR3 Extension Study United States, Canada and Europe GHD children completing a somavaratan study 95% of Phase 2a patients rolled over into long-term safety study Currently 48 Subjects continue in study GHD children completing Phase 3 on daily rhGH offered op

  41. Slide 41: PGHD Study Results: Reported Treatment Adherence

    PGHD Study Results: Reported Treatment Adherence after 30 Months Somavaratan Exposure Parameter Somavaratan Starting Regimen Somavaratan Phase 3 Regimen 5.0 mg/kg Monthly (n=22) 2.5 mg/kg Twice-Monthly (n=18) 1.15 mg/kg Weekly* (n=20) 3.5 mg/kg Twice-Monthly (n=58) Doses Completed/Expected 131/131 2

Versartis — Investor Presentation (November 2016) on 6ix